IBSA is a privately-owned pharmaceutical company, founded in Lugano in 1945 by a group of Swiss biologists.
A turning point in IBSA’s history was in 1985, when the current management took over the company, fully redefining its vision and strategy, placing IBSA on the international scene for the first time. After taking its first steps on the domestic market, IBSA embarked upon an exceptional and intensive development programme with the aim of expanding company assets and creating a competitive portfolio of products covering 9 main therapeutic areas, which have resulted in IBSA holding a leading position in the world markets. Thanks to its consolidated expansion strategy, IBSA products are marketed in 5 continents and in more than 80 countries, including China and the United States. As a result of this extensive expansion, the Group employs a total of 1400 people, distributed among the various offices and production sites, and has 10 branches in Europe, China and the United States, as well as 14 Research and Development laboratories in the world employing 116 people.
The company also has 1 strategic partnership represented by Laboratoires Genevrier in France, which add a further 200 people to the workforce, making a total of 1600 employees.
From 1985 to the present date, 400 million Swiss francs have been invested in human resources, production capacity and innovation.
Currently, IBSA is the largest privately-owned pharmaceutical company in Switzerland, the four largest operator, after the major multinationals, in the Fertility sector, and a world leader in hyaluronic acid-based products.
Via del Piano 29, PO Box 266
|T.: +41 58 360 10 00|
|F.: +41 58 360 16 77|
Main activities Licensing-In ● Licensing-Out ● Drug Product CMO ● Drug Substance CMO ●
Drug stages Pre-clinical ● Phase I - Phase III ● Registration ● Market ● Generic Plus (505B2) ● Life cycle management ●
Therapeutic areas Cardiovascular ● Dermatology ● Endocronology ● Gynaecology ● Infertility ● Orthopedics ● Pain ● Respiratory ● Rheumatology ● Other ●
Markets CH ● EU Top 5 ● Rest of Europe ● USA and Canada ● LATAM ● MENA ● BRICS ● ASEAN ● Africa ● Australia ● Korea ●
Drug product forms Aerosol ● Inhaler ● Injectable ● Oral (solid) ● Oral (liquid) ● Spray ● Topical ● Other ●
Drug substance type APIs (1-10kgs/batch) ○ Chondroitin sulfate ● Gonadotropins ● Hyaluronic acid ● Steroids ● Other ●
Other activities (non pharma) Analytical Services ● Cosmetics ● Distribution ● Flavours and Fragrances ● Medical Devices ● Medical Food ● Nutraceuticals ● Pre-formulation ●